Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V3CM
|
|||
| Former ID |
DNC012436
|
|||
| Drug Name |
Opaviraline
|
|||
| Synonyms |
Opaviraline; GW420867X; UNII-Q3A8EU2NMU; 178040-94-3; Q3A8EU2NMU; GW-420867X; Isopropyl (2s)-2-Ethyl-7-Fluoro-3-Oxo-3,4-Dihydroquinoxaline-1(2h)-Carboxylate; isopropyl (2S)-2-ethyl-7-fluoro-3-oxo-2,4-dihydroquinoxaline-1-carboxylate; Opaviraline [INN]; HBQ; AC1L4BLF; SCHEMBL464732; Opaviraline (GW 420867); CHEMBL301370; BDBM2955; GW 867X; HBY1293; DTXSID60170415; GW867; HBY1293/GW867; ZINC3916138; HBY-1293; GW-867; AKOS027326866; DB07884; 1(2H)-Quinoxalinecarboxylic acid,2-ethyl-7-fluoro-3,4-dihydro-3-oxo-,1-methylethyl ester,(2S)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Discontinued in Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H17FN2O3
|
|||
| Canonical SMILES |
CCC1C(=O)NC2=C(N1C(=O)OC(C)C)C=C(C=C2)F
|
|||
| InChI |
1S/C14H17FN2O3/c1-4-11-13(18)16-10-6-5-9(15)7-12(10)17(11)14(19)20-8(2)3/h5-8,11H,4H2,1-3H3,(H,16,18)/t11-/m0/s1
|
|||
| InChIKey |
KELNNWMENBUHNS-NSHDSACASA-N
|
|||
| CAS Number |
CAS 178040-94-3
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Reverse transcriptase (HIV RT) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011603) | |||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.